PODD · Insulet Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.70M | - | $706.30M | $649.10M | $569.00M | - | $543.90M | $488.50M | $441.70M | - |
| Cost of Revenue | $232.70M | - | $196.20M | $196.90M | $160.00M | - | $166.80M | $157.60M | $134.90M | - |
| Gross Profit | $529.10M | - | $510.10M | $452.20M | $409.00M | - | $377.10M | $330.90M | $306.80M | - |
| R&D | $89.70M | - | $77.20M | $73.40M | $59.60M | - | $54.90M | $53.90M | $50.20M | - |
| SG&A | $317.20M | - | $315.20M | $257.70M | $260.60M | - | $234.10M | $222.40M | $199.70M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $26.20M | - | - | - | $21.70M | - | - | - | $18.80M | - |
| Operating Income | $122.10M | - | $117.70M | $121.10M | $88.80M | - | $88.10M | $54.60M | $56.90M | - |
| Interest Expense | $14.70M | - | $15.60M | $19.60M | $10.70M | - | $12.30M | $11.00M | $10.70M | - |
| Income Tax | $21.90M | - | $35.20M | $5.90M | $12.70M | - | $5.40M | ($137.50M) | $3.40M | - |
| Net Income | $91.10M | - | $87.60M | $22.50M | $35.40M | - | $77.50M | $188.60M | $51.50M | - |
| EPS - Basic | $1.30 | - | $1.24 | $0.32 | $0.50 | - | $1.11 | $2.69 | $0.74 | - |
| EPS - Diluted | $1.30 | - | $1.24 | $0.32 | $0.50 | - | $1.08 | $2.59 | $0.73 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $480.40M | $716.10M | $757.40M | $1.12B | $1.28B | $953.40M | $902.60M | $821.00M | $751.20M | $704.20M |
| Accounts Receivable | $516.90M | - | - | - | - | - | - | - | - | - |
| Inventory | $462.50M | $452.60M | $446.30M | $446.90M | $440.80M | $430.40M | $444.90M | $430.90M | $430.60M | $402.60M |
| Accounts Payable | $149.80M | $75.00M | $48.20M | $96.10M | $57.60M | $19.80M | $40.30M | $76.80M | $75.90M | $19.20M |
| Current Assets | $1.71B | $1.91B | $1.86B | $2.28B | $2.33B | $1.89B | $1.86B | $1.75B | $1.62B | $1.58B |
| Total Assets | $2.99B | $3.19B | $3.03B | $3.47B | $3.52B | $3.09B | $3.03B | $2.88B | $2.62B | $2.59B |
| Current Liabilities | $687.50M | $680.10M | $647.70M | $1.01B | $520.40M | $528.40M | $506.20M | $486.00M | $432.40M | $451.20M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.68B | $1.68B | $1.65B | $2.01B | $2.19B | $1.88B | $1.91B | $1.88B | $1.83B | $1.86B |
| Stockholders' Equity | $1.30B | $1.52B | $1.38B | $1.46B | $1.33B | $1.21B | $1.12B | $998.40M | $790.70M | $732.70M |
| Retained Earnings | $378.50M | $287.40M | $185.80M | $98.20M | $75.70M | $40.30M | ($60.40M) | ($137.90M) | ($326.50M) | ($378.00M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $113.80M | - | - | - | $63.80M | - | - | - | $87.60M | - |
| Investing Cash Flow | ($27.70M) | - | - | - | ($15.70M) | - | - | - | ($24.00M) | - |
| Financing Cash Flow | ($319.90M) | - | - | - | $277.80M | - | - | - | ($14.10M) | - |
| CapEx | $24.30M | - | - | - | $12.30M | - | - | - | $22.10M | - |
| Free Cash Flow | $89.50M | - | - | - | $51.50M | - | - | - | $65.50M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 69.5% | - | 72.2% | 69.7% | 71.9% | - | 69.3% | 67.7% | 69.5% | - |
| Operating margin | 16.0% | - | 16.7% | 18.7% | 15.6% | - | 16.2% | 11.2% | 12.9% | - |
| EBITDA margin | 19.5% | - | - | - | 19.4% | - | - | - | 17.1% | - |
| Net margin | 12.0% | - | 12.4% | 3.5% | 6.2% | - | 14.2% | 38.6% | 11.7% | - |
| Free cash flow margin | 11.8% | - | - | - | 9.1% | - | - | - | 14.8% | - |
| FCF / Net income | 0.98 | - | - | - | 1.45 | - | - | - | 1.27 | - |
| R&D / Revenue | 11.8% | - | 10.9% | 11.3% | 10.5% | - | 10.1% | 11.0% | 11.4% | - |
| SG&A / Revenue | 41.6% | - | 44.6% | 39.7% | 45.8% | - | 43.0% | 45.5% | 45.2% | - |
| Effective tax rate | 19.4% | - | 28.7% | 20.8% | 26.4% | - | 6.5% | -269.1% | 6.2% | - |
| Return on assets | 3.0% | - | 2.9% | 0.6% | 1.0% | - | 2.6% | 6.5% | 2.0% | - |
| Return on equity | 7.0% | - | 6.3% | 1.5% | 2.7% | - | 6.9% | 18.9% | 6.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.49 | 2.81 | 2.87 | 2.26 | 4.47 | 3.58 | 3.68 | 3.60 | 3.74 | 3.51 |
| Quick ratio | 1.81 | 2.15 | 2.18 | 1.81 | 3.63 | 2.76 | 2.80 | 2.71 | 2.75 | 2.62 |
| Cash ratio | 0.70 | 1.05 | 1.17 | 1.11 | 2.47 | 1.80 | 1.78 | 1.69 | 1.74 | 1.56 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 8.3x | - | 7.5x | 6.2x | 8.3x | - | 7.2x | 5.0x | 5.3x | - |
| Equity multiplier | 2.29 | 2.11 | 2.19 | 2.37 | 2.64 | 2.55 | 2.71 | 2.89 | 3.32 | 3.53 |
| Liabilities / Assets | 0.56 | 0.53 | 0.54 | 0.58 | 0.62 | 0.61 | 0.63 | 0.65 | 0.70 | 0.72 |
| Efficiency | ||||||||||
| Asset turnover | 0.25 | - | 0.23 | 0.19 | 0.16 | - | 0.18 | 0.17 | 0.17 | - |
| Inventory turnover | 0.50 | - | 0.44 | 0.44 | 0.36 | - | 0.37 | 0.37 | 0.31 | - |
| Days sales outstanding | 248d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 725d | - | 830d | 828d | 1006d | - | 974d | 998d | 1165d | - |
| Days payable outstanding | 235d | - | 90d | 178d | 131d | - | 88d | 178d | 205d | - |
| Cash conversion cycle | 738d | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 161.4x | - | 249.0x | 981.8x | 525.2x | - | 215.5x | 77.9x | 234.8x | - |
| P / B | 11.3x | - | 15.8x | 15.2x | 14.6x | - | 15.4x | 14.9x | 16.0x | - |
| P / S | 19.3x | - | 30.9x | 34.2x | 34.2x | - | 31.6x | 30.5x | 28.6x | - |
| EV / EBITDA | 96.1x | - | - | - | 164.5x | - | - | - | 157.0x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 33.9% | - | 29.9% | 32.9% | 28.8% | - | 25.7% | 23.2% | 23.3% | - |
| Revenue CAGR (3y) | 28.6% | - | 35.8% | 29.4% | 31.1% | - | 25.4% | 22.9% | 20.5% | - |
| Revenue CAGR (5y) | 24.7% | - | 24.7% | 23.5% | 23.5% | - | 23.1% | 22.5% | 22.6% | - |
| Gross profit growth (YoY) | 29.4% | - | 35.3% | 36.7% | 33.3% | - | 28.6% | 24.9% | 27.6% | - |
| Operating income growth (YoY) | 37.5% | - | 33.6% | 121.8% | 56.1% | - | 60.8% | 75.6% | 105.4% | - |
| Net income growth (YoY) | 157.3% | - | 13.0% | -88.1% | -31.3% | - | 49.3% | 590.8% | 116.4% | - |
| EPS growth (YoY) | 160.0% | - | 14.8% | -87.6% | -31.5% | - | 45.9% | 564.1% | 114.7% | - |
| EPS CAGR (3y) | 56.4% | - | - | - | 7.7% | - | 81.7% | - | - | - |
| EPS CAGR (5y) | - | - | 48.8% | 7.8% | - | - | 155.1% | 164.5% | 59.8% | - |
| FCF growth (YoY) | 73.8% | - | - | - | -21.4% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -2.1% | 25.1% | 23.8% | 46.5% | 68.3% | 65.4% | 84.0% | 80.2% | 57.3% | 53.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$5.38B totalProduct Omnipod$2.67B · 49.7%
U.S.Omnipod$1.92B · 35.7%
International Omnipod$754.30M · 14.0%
Drug Delivery$34.10M · 0.6%
Geographic
$2.71B totalUS$1.95B · 72.1%
Non Us$754.30M · 27.9%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing INSULET CORP against the 5 most active filers in the same SIC group.